# FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

> **NCT04245722** · PHASE1 · TERMINATED · sponsor: **Fate Therapeutics** · enrollment: 98 (actual)

## Conditions studied

- Lymphoma, B-Cell
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** FT596
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Rituximab
- **DRUG:** Obinutuzumab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT04245722
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-19
- **Primary completion:** 2023-09-27
- **Final completion:** 2023-09-27
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** The study was terminated by the Sponsor.
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04245722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04245722, "FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04245722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*